ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies.

This study has been terminated.
(Recruitment too slow. Number of eligible patients probably to low. Patients enrolled and/or in follow-up will be followed up in the Valeo study.)
Sponsor:
Information provided by:
Janssen-Cilag B.V.
ClinicalTrials.gov Identifier:
NCT00440479
First received: February 26, 2007
Last updated: November 4, 2010
Last verified: November 2010
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: July 2011
  Estimated Primary Completion Date: No date given